Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma

Source :: PR Newswire. June 25, 2024
Publication Year :: 2024
Abstract: HyBryte(TM) demonstrates more rapid and robust treatment response compared to Valchlor during 12-week treatment course PRINCETON, N.J., June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), [...]

Subjects :: United States. Food and Drug Administration
T cells -- Comparative analysis
Non-Hodgkin's lymphomas -- Care and treatment
Skin -- Comparative analysis
Business
News, opinion and commentary
Valchlor (Medication) -- Comparative analysis

Tools